

SPECIAL eBULLETIN

FOR PROFESSIONAL AND FACILITY PROVIDERS

MAY 26, 2017

ATTENTION ORDERING PHYSICIANS, LABS, HOSPITAL LABS:

LABORATORY MANAGEMENT PROGRAM CHANGES TO OCCUR ON JUNE 30, 2017, AND JULY 31, 2017

eviCore manages molecular and genomic testing within the Laboratory Management Program to ensure that the genetic lab services provided to Highmark's members support clinically appropriate care and are medically necessary, in accordance with their benefit policy.

Certain changes will take effect for the Laboratory Management Program on June 30, 2017, and July 31, 2017, as indicated below.

NEW PLA CODES ADDED TO EVICORE LABORATORY MANAGEMENT PROGRAM JUNE 30, 2017

eviCore is updating the Laboratory Management Program by adding Proprietary Laboratory Analyses (PLA) codes to the program. PLA codes, created by the American Medical Association (AMA), are alphanumeric CPT® codes that are a new addition to the CPT code set. PLA codes were created for labs or manufacturers that want to more specifically identify their test.

The AMA will develop PLA codes on a quarterly basis. In conjunction with the AMA's PLA code creation process, eviCore will make coding updates to the Laboratory Management Program.

The following PLA procedure codes will be subject to prior authorization or claims review, as part of our Laboratory Management Program. The procedure codes that represent these services become effective on June 30, 2017.

Proprietary Laboratory Analyses Procedure Code Additions				
New PLA Code	Description	Test	Laboratory Management Program Requirement	Previous Procedure Code(s)
0001U	Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported	PreciseType® HEA Test, Immucor, Inc.	Prior authorization	81403



Proprietary Laboratory Analyses Procedure Code Additions

New PLA Code	Description	Test	Laboratory Management Program Requirement	Previous Procedure Code(s)
0004U	Infectious disease (bacterial), DNA, 27 resistance genes, PCR amplification and probe hybridization in microarray format (molecular detection and identification of AmpC, carbapenemase and ESBL coding genes), bacterial culture colonies, report of genes detected or not detected, per isolate	Gram-Negative Bacterial Resistance Gene PCR Panel, Mayo Clinic, Check-Points Health BV, Wageningen, Netherlands	Claims review	87150
0005U	Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score	ExosomeDx [®] Prostate (IntelliScore), Exosome Diagnostics, Inc.	Prior authorization	81599, 84999

PLA codes 0001U and 0005U will require prior authorization beginning with dates of service on or after June 30, 2017, when performed in an outpatient setting for fully-insured Commercial, Affordable Care Act, and Medicare Advantage members. If these services are performed without prior authorization, Highmark will deny them. In this instance, you may not seek reimbursement from the member.

PLA code 0004U will be reviewed for accuracy and medical necessity based on eviCore's policies.

EVICORE REVISES LABORATORY MANAGEMENT CLINICAL GUIDELINES, EFFECTIVE JULY 31, 2017

eviCore is revising its Laboratory Management Clinical Guidelines by adding new guidelines, retiring guidelines, and making changes to certain criteria. We will amend our clinical guidelines based on eviCore's modifications. Please review the [Executive Summary](#) for an explanation of eviCore's revisions. You can find more details at evicore.com/healthplan/highmark_lab.

To learn more about the Laboratory Management Program and how to submit prior authorization requests through eviCore, please visit the **Laboratory Management Program** page, located under **Clinical Reference Materials** on the Provider Resource Center.